casimersen - Profile

What are the generic sources for casimersen and what is the scope of patent protection?

Casimersen is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Casimersen has eighty-eight patent family members in twenty-five countries.

Summary for casimersen

International Patents:	88
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for casimersen

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for casimersen

Constraining patent/regulatory exclusivity:

TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for casimersen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	9,758,783
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	10,781,450
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	RE48960		Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	10,287,586		Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	9,228,187		Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes

Expired US Patents for casimersen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021	10,533,174
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021	9,416,361
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021	8,524,880
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021	9,447,415

International Patents for casimersen

Country	Patent Number	Title	Estimated Expiration
Australia	2016202924	Antisense molecules and methods for treating pathologies
South Korea	20220031125	안티센스 분자 및 이를 이용한 질환 치료방법 (Antisense Molecules and Methods for Treating Pathologies)
Israel	276947	אוליגונוקלאוטידי אנטיסנס לגרימת דילוג אקסון בגן דיסטרופין (Antisense oligonucleotides for inducing exon skipping in the dystrophin gene)
Poland	2206781
Serbia	58079	ANTISENS MOLEKULI I POSTUPCI ZA TRETMAN PATOLOGIJA (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
European Patent Office	3431603	MOLÉCULES ANTISENS ET PROCÉDÉS DE TRAITEMENT DE PATHOLOGIES (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)

Casimersen: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Casimersen (brand name Amondys 45) is an antisense oligonucleotide developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) caused by specific genetic mutations. This article analyzes the drug’s investment landscape, market conditions, and financial outlook based on recent clinical and commercial developments. Key factors include regulatory milestones, competitive landscape, patient population estimates, and anticipated revenue trajectories.

---

Introduction to Casimersen

Attribute	Details
Drug Class	Antisense oligonucleotide (ASO)
Indication	DMD in patients with exon 45 skipping mutation
Developer	Sarepta Therapeutics, Inc.
Approval Status	FDA-approved (February 2021) under Accelerated Approval pathway
Development Stage	Commercialized; ongoing real-world use; pipeline expansion potential

---

Market Dynamics & Disease Context

Key Parameter	Details
DMD Prevalence	~1 in 3,500 to 5,000 male births globally (approx. 15,000–20,000 patients in the U.S.)
Genetic Mutation Specifics	Exon skipping therapies target specific mutations, such as exon 45 deletion (~8-10% of DMD patients)
Current Treatment Landscape	Limited options: eteplirsen (Exondys 51), viltolarsen (Viltepso), other experimental antisense therapies
Market Size for Casimersen	Estimated ~800–2,000 U.S. patients with exon 45 skipping mutation

Regulatory & Commercial Milestones

Milestone	Date	Impact
FDA Approval (FDA PDUFA)	February 2021	First exon 45 skipping therapy approved, establishing Sarepta’s foothold
Pricing & Reimbursement	$300,000 annually (per patient)	Reflects premium pricing, influenced by orphan drug designation and unmet need
Expansion and Access	Post-approval, expanding indications and geographic reach	Increasing overall market penetration

---

Financial Trajectory Analysis

Revenue Projections & Market Uptick

Year	Estimated Patients (U.S.)	Revenue (USD Million)	Notes
2021	500	150	Initial uptake; limited distribution
2022	700	210	Growing awareness and reimbursement uptake
2023	900	270	Expanded access; pipeline support
2024	1,200	360	Increased disease awareness, market penetration
2025	1,500	450	Peak, considering market saturation and pipeline development

Assumptions:

• Stable pricing at ~$300,000/year per patient
• Incremental growth as awareness improves and insurance coverage expands
• Potential for biosimilar or generic competition minimal in first 5 years due to orphan drug exclusivity (10-year market exclusivity in the U.S.)

Cost Considerations

Item	Estimated Impact	Notes
Research & Development	~$200M (total, ongoing)	Phase 3 trials, pipeline expansion
Manufacturing Costs	~$50,000 per patient/year	Biologics production complexity
Commercial Operations	~$75M annually	Sales, marketing, distribution

Profitability Outlook

Metric	2021	2023	2025
Gross Margin	Estimated 70%	Stabilized	Maintained
EBITDA Margin	Approx. 20-25%	Improving	Approaching 30%

---

Competitive Landscape

Competitors	Focus	Market Position	Key Differentiators
Eteplirsen (Exondys 51)	Exon 51 skipping	First-mover advantage	Clinical efficacy debates
Viltolarsen (Viltepso)	Exon 53 skipping	Approved in Japan, limited in US	Similar mechanism, smaller market share
Experimental Agents	Multiple exon skipping	Early clinical development	Variable efficacy, higher risk

Casimersen’s competitive edge lies in its targeted mechanism for exon 45 mutations, providing a treatment option where few, if any, exist. Its approval broadens the landscape but remains niche within the overall DMD market.

---

Market Penetration & Expansion Opportunities

Opportunity	Potential Impact	Timeline	Strategic Considerations
Broaden Geographic Access	Increased revenues	2023-2025	Regulatory approvals in EU/Japan
Pipeline Expansion	New indications or mutations	2023-2027	Investigate exon 44, 53, or multi-exon skipping
Combination Therapies	Enhanced efficacy	2024+	Collaborate with gene therapy developers
Pricing & Reimbursement Strategies	Maximize revenue	Ongoing	Engage payers early, demonstrate value

---

Investment Analysis & Risks

Key Factors	Evaluation	Potential Risks
Market Size & Growth	Niche but scalable	Mutation-specific limit
Regulatory Landscape	Favorable through accelerated pathways	Post-market safety concerns
Patent & Exclusivity Life	10-year market exclusivity	Patent challenges; biosimilar threats post-2029
Manufacturing & Supply Chain	Complex but established	Disruptions impacting supply and margins
Competitive Innovation	Emerging therapies in development	Loss of exclusivity or market share

Comparison with Competing Treatments

Attribute	Casimersen	Eteplirsen	Viltolarsen
Mechanism	Exon 45 skipping	Exon 51 skipping	Exon 53 skipping
Regulatory Status	Approved	Approved	Approved (Japan)
Pricing	~$300,000/year	Similar (~$300,000)	Similar (~$250,000)
Market Share (Est.)	Growing	Established	Limited

---

Potential Future Developments

• Pipeline Expansion: Sarepta and other biotech firms are exploring multi-exon skipping, gene editing (CRISPR-based), and gene therapy options.
• Digital & Real-World Evidence (RWE): Increasing use of RWE for reimbursement and market access decisions.
• Legislative & Policy Changes: Orphan drug incentives likely to remain strong, but pricing pressures may intensify.

---

Key Takeaways

• Market Opportunity: Casimersen addresses a niche subset of DMD (~8-10%) with significant unmet need. Estimated U.S. patient population is approximately 800–2,000 individuals.
• Revenue Potential: Projected to reach ~$450M annually by 2025, with growth driven by increased uptake and geographic expansion.
• Competitive Position: First-mover advantage within its mutation-specific niche, although smaller in scope compared to broader exon skipping therapies.
• Risks & Challenges: Limited mutation specificity constrains market size; potential biosimilar threats post-expiration of exclusivity; ongoing pipeline developments pose competitive threats.
• Investment Outlook: Stable growth with upside from pipeline and geographic expansion. Valuation will be sensitive to regulatory outcomes, reimbursement policies, and clinical trial results for expanded indications.

---

FAQs

Q1: How does Casimersen differ from other exon skipping therapies?
A1: Casimersen specifically targets exon 45 skipping mutations in DMD, filling a treatment gap for patients with this rare genetic defect—unlike eteplirsen (exon 51) or viltolarsen (exon 53).

Q2: What is the current market size for Casimersen?
A2: The estimated U.S. patient population with exon 45 deletion is approximately 800–2,000 individuals, representing a niche but valuable segment.

Q3: What are the main risks associated with investing in Casimersen?
A3: Risks include small market size, potential competition from emerging therapies, biosimilar threats post-patent expiry, and uncertainty regarding long-term clinical efficacy.

Q4: How is reimbursement likely to evolve for Casimersen?
A4: Reimbursement is currently favorable at ~$300,000 per year. However, future negotiations and healthcare policy changes could influence pricing and coverage.

Q5: What are the prospects for pipeline expansion?
A5: Sarepta continues exploring multi-exon skipping and gene editing, which could expand the treatment landscape, potentially increasing the overall market opportunity.

---

References

1. FDA Approval Summary for Amondys 45 (Casimersen), U.S. FDA, 2021.
2. Duchenne Muscular Dystrophy Epidemiology, Muscular Dystrophy Association, 2022.
3. Sarepta Therapeutics Financial Reports, 2022-2023.
4. Market Analysis: Exon Skipping Therapies for DMD, GlobalData, 2023.
5. Orphan Drug Designations & Exclusivities, FDA, 2022.

---

This comprehensive analysis provides a strategic view for investors, biotech executives, and healthcare stakeholders assessing Casimersen’s current positioning and future potential within the expanding landscape of personalized therapies for rare genetic disorders.